## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.44 indicates fundamental undervaluation. Quality metrics strong (ROE 20%, ROA 13%). Caution: declining volume (58% of avg), momentum weakening (-3.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($455.95)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($11.95M) |
| Sells | 70 ($38.89M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $39M sold (70 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 16.8x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($38.9M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.9B |
| Beta | 0.86 |
| 52W Range | $266.98 - $492.62 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 16.8 |
| Current P/E | 17.7 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.4% to 1.9% (-3.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.1pp (needs >4.0% for momentum thesis). MRS_5 (-1.3%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). Volume at 58% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.85% (CS: 71) | Neutral |
| RSI_14 | 64.9 | Neutral |
| MACD Histogram | 0.48 | Bullish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.073x | Above |
| vs SMA200 | 1.381x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $479.95
- **Stop Loss:** $455.95 (5.0% risk)
- **Target:** $527.95 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $14,878.45
- **Portfolio %:** 14.88%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*